Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
Completed
Cumberland Pharmaceuticals
Phase 2
A study of ifetroban in the treatment of hepatorenal syndrome (HRS) in hospitalized adult
patients to assess the safety and pharmacokinetics of 3 days of intravenous ifetroban.
Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
Completed
Cumberland Pharmaceuticals
Phase 2
The primary objective of the study is to determine the safety of oral ifetroban compared to
placebo as measured by a > 20% decrease in FEV1 compared to baseline following a dose of
Investigational Medicinal Product (IMP) (Study Day 1 or 2) prior to initiation of the aspirin
challenge.
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Recruiting
Cumberland Pharmaceuticals
Phase 2
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study
is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic
SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients
Completed
Cumberland Pharmaceuticals
Phase 2
This placebo-controlled study will assess the safety and efficacy of a 90-day course of
treatment with ifetroban for portal hypertension in cirrhotic patients
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
